pentapeptide

Ipamorelin

US: Not on the registerEU: Not on the registerUK: Not on the registerCA: Not on the registerAU: Status unknownCH: Not on the registerBR: Not on the registerRS: Not on the registerSG: Not on the registerTR: Not on the register

Answer

Ipamorelin is not authorised on any of the 10 registers read, and 1 of them holds no reading for it. No trial states a phase. It has 3 registered trials, 1 of them running.

RegulatorTrial register10 regulators' registers, read 2026-08-31 to 2026-10-03 · ClinicalTrials.gov, read 2026-10-03

Not medical, legal or regulatory advice.

Registered trials3Trial register ClinicalTrials.gov

Running now1Trial register recruiting, active or enrolling

Results posted0Trial register with results on the register

Stopped early0%Trial register all peptides: 10%

3 trials by status

Trial register

Running 1Completed 2

ClinicalTrials.gov · read 2026-10-03 · 0 trials have posted results

Trials first submitted per year

Trial register

12008

12011

12026

ClinicalTrials.gov first-submitted date, last 3 years · read 2026-10-03. 2026 is not complete.

Status by jurisdiction

World map

CAISNOUSUKEUUACNKRJPMXCHLIRSTRINTHBREGILSAAESGARZAAUNZ

Authorised or registeredNot on the register, or withdrawnNot read yet, or status unknown

Where	Status	Register	Read
United States	Not on the register	FDA, openfda	2026-10-03
European Union	Not on the register	EMA, ema	2026-08-31
United Kingdom	Not on the register	MHRA, uk-mhra	2026-09-03
Canada	Not on the register	Health Canada, ca-dpd	2026-09-03
Australia	Status unknown	TGA, au-artg	not read
Switzerland	Not on the register	Swissmedic, ch-swissmedic	2026-09-03
Brazil	Not on the register	ANVISA, br-anvisa	2026-09-03
Serbia	Not on the register	ALIMS, rs-alims	2026-09-03
Singapore	Not on the register	HSA, sg-hsa	2026-09-03
Turkey	Not on the register	TITCK, tr-titck	2026-09-03

An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.

CHANGE ALERTS

Get an email when this changes

One email when the status of Ipamorelin changes on the register. You confirm your address first.

ENFORCEMENT AND OFFICIAL ACTIONS

2 actions by named authorities

Enforcement actions, board positions and payer rules that name Ipamorelin, quoted from the source document. These are not approval decisions. This list shows the actions found so far. It is not a complete list: no authority publishes one.

US-OHenforcement

Ohio Board of Pharmacy, 2026-04-16

During the inspection, [redacted] was found to possess multiple vials of the following illegal dangerous drugs, in either a white powder, purple powder, or clear liquid form, intended for injection, which were obtained from an unlicensed, foreign source: m. Ipamorelin 10mg, 5 vials;

State of Ohio Board of Pharmacy, Order, Case No. A-2026-0037, Findings of Fact paragraph 2(m) · quoted with the party redacted

US-CAenforcement

California Board of Pharmacy, 2023-12-04

Ipamorelin is a synthetic product derived from GHRP-1 (Growth Hormone Releasing Peptide-1). Ipamorelin is a pentapeptide, consisting of five amino acids and is therefore a peptide. It is a dangerous drug pursuant to Code section 4022.

California Board of Pharmacy, First Amended Accusation and First Amended Statement of Issues, Case Nos. 7160 and 7171, paragraph 29

REGISTERED TRIALS

3 trials, newest first

NCT07717866	Trifecta Research Study running, but no longer enrolling · register updated 2026-07-21
NCT00672074	Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus completed · register updated 2017-04-14
NCT01280344	Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function completed · register updated 2017-04-13

All peptides · Method

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.